D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

Krear agrees that 2025 will be a year to watch with more than 58 EV retail models available and a two-year high in the number of new vehicle shoppers that are self-described as "very likely" to ...